FDA WARNING_LETTER - Amazing Meds - August 31, 2025

**FDA Warning Letter Summary**

**Company:** Amazing Meds **Location:** 5777 North Academy Blvd, Colorado Springs, CO 80918, United States **Date of Letter:** September 9, 2025 **Inspection Date:** August 2025

**Main Violations/Issues:** The FDA reviewed Amazing Meds" website and identified significant regulatory violations concerning their compounded drug products, specifically retatrutide and semaglutide. The retatrutide products are classified as unapproved new drugs and misbranded drugs, violating sections 505(a), 502(f)(1), 301(a), and 301(d) of the Federal Food, Drug, and Cosmetic Act (FDCA). These products lack FDA approval and are not eligible for exemptions under sections 503A and 503B of the FDCA, as they do not meet the necessary conditions, such as being listed on the 503A or 503B bulks list.

Additionally, the semaglutide products are misbranded due to false or misleading claims on the company"s website, implying equivalence to FDA-approved drugs like Ozempic/Wegovy. This misrepresentation violates sections 502(a) and 502(bb) of the FDCA.

**Regulatory Framework:** The violations fall under the FDCA, which governs the approval and marketing of drug products. Sections 503A and 503B outline conditions for compounding exemptions, which Amazing Meds failed to meet.

**Required Actions:** Amazing Meds must cease the introduction of these unapproved and misbranded drugs into interstate commerce. They are required to address the violations by ensuring compliance with FDA regulations, including obtaining necessary approvals and correcting misleading claims. The FDA expects a prompt response detailing corrective actions taken to address these issues.